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1. Introduction 
Several discoveries and inventions in medicine have revolutionized it’s practice. Examples 
would include the discovery of Insulin by Dr William Banting in 1920. The discovery of 
Heparin by Dr Jay McLean and its first clinical use in Toronto in 1933-36, the advent of the 
membrane oxygenator, heart lung machines with progressively smaller footprints, intra 
aortic balloon (IAB) pumps and VAD’s (ventricular assist device) would be some of the 
devices which significantly impacted outcomes in cardiac surgery. 
The fundamentals of IAB technology were first tested by Harken in 1958, who is credited 
with the first use of diastolic augmentation. The pump for Harken’s system was a failure 
due to massive hemolysis. Moulopoulous (in the 1960’s) from the Cleveland Clinic 
developed the first successful prototype of an Intra-aortic balloon pump (IABP) which could 
be timed to the cardiac cycle. 
The IABP device as we know it was reported by Dr Adrian Kantrowitz (Fig 1) and his team 
from Grace Sinai hospital in Detroit. The first clinical implant was performed at Maimonides 
Medical Centre, Brooklyn, NY in Oct 1967 for a 48 yr old woman in cardiogenic shock 
unresponsive to traditional therapy. The IAB was inserted through a cut down of the left 
femoral artery (LFA) and pumping performed for 6 hrs. The shock was reversed and the 
patient discharged. The device was further developed for cardiac surgery by Dr David 
Bregman at New York Presbyterian Hospital in 1976. 
Studying the history of counterpulsation elucidates the great strides in IAB technology and 
its clinical applications. The size of the balloons initially inserted were as large as 15 Fr. Two 
operations were required for balloon usage, one to insert the balloon by cut down in a 
femoral artery, and a second operation to remove the balloon. Advances in technology 
afforded progressively smaller IAB catheter sizes and eventually 8 and 9Fr. balloons were 
developed. Current IAB catheter sizes are 7 and 7.5Fr. 
In 1968 –Kantrowitz and his group began to use the IABP regularly in clinical practice. 
Since 1979 balloon placement utilizes the Seldinger (percutaneous) technique. 
The wrapped IAB was developed in 1985. Advances in technology facilitated graduating 
from cut down insertions to percutaneous and sheathless insertions going from cut down 
insertions to percutaneous and finally sheathless insertions. Smaller diameter catheters 
permitted this along with user friendly consoles with automated and real time timing 
algorithms. 
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Fig. 1. Datascope System 80 
2. Fundamentals of cardiac physiology 
Understanding of counterpulsation, requires a knowledge of relevant cardiovascular 
physiology. The heart works as a series circuit of pumps, the left system and the right 
system.  
The right atrium (RA) receives blood from the inferior and superior vena cava and coronary 
sinus, most of which flows passively into the right ventricle (RV) through the tricuspid 
valve. An additional 20% of ventricular filling occurs through the atrial kick corresponding 
to the “p” wave of the Electrocardiogram (ECG). (Quaal 1993) 
The right system feeds the low pressure pulmonary vasculature which offers little resistance 
to the blood ejected from the right ventricle (RV). Consequently the right ventricular 
musculature is one third the girth of the Left Ventricle. The left atrium receives blood from 
four pulmonary veins and passively empties the blood into the left ventricle through the 
mitral valve. Since there are no valves in the pulmonary veins, elevation of left atrial 
pressure results in an increase in pulmonary vascular resistance (PVR). 
Generation of high pressure is required by the left ventricle, most of the pressure being 
generated occurs during isovolumetric contraction (Fig2-phases of contraction-electrical and 
mechanical) in order to open the aortic valve, and overcome SVR and aortic end diastolic 
pressure (AEDP), which is a function of the systemic vascular resistance.  
The intraventricular septum also contributes to the left ventricular ejection along with the 
thick circular posterior and lateral walls. 
Some of the energy imparted to the blood through ventricular ejection is stored in the 
proximal aorta and large arteries as potential energy during their peak expansion. This is 
known as the Windkessel effect. In diastole, this energy is transformed into kinetic energy 
by the aorta and large arteries causing a recoil, which maintains a pressure head in the aorta. 
This in turn maintains a runoff during diastole into the peripheral arteries. It’s important to 
note that coronary arteries fill during diastole. 
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Fig. 2. Phases of electrical and mechanical contraction 
3. Cardiac output 
Cardiac output is the product of stroke volume and heart rate. Stroke volume is the amount 
of blood ejected by the Left Ventricle with every beat. 
Stroke volume is dependent on 
1. Preload 
2. Afterload 
3. Inotropy or (ventricular contractility) and 
4. Heart rate 
4. Preload 
This concept suggests that the length of ventricular muscle fiber determines the magnitude 
of contraction. The length of the LV muscle fiber in turn is dependent upon the left 
ventricular end diastolic volume (LVEDP). In other words increase in left atrial filling would 
increase the magnitude of LV contraction. The ability of the LV to vary the strength of its 
contraction as a function of the LVEDP and end diastolic muscle fiber length is defined as 
Frank Starling law (fig 3). This gain in contractility is impaired when the stretch goes 
beyond physiological limits. In clinical practice the length of the muscle fiber is proportional 
to the LVEDP ’which is measured indirectly as the pulmonary artery wedge pressure 
(PAWP) by means of a Swan Ganz catheter. In a normal LV, very slight changes in PAWP or 
LVEDP, produces significant increases in stroke volume. 
5. Afterload 
Afterload is defined as the resistance to LV ejection. Major components are SVR and 
AEDP. AEDP is the resistance the LV has to overcome in order to open the aortic valve. 
Ninety percent of myocardial oxygen consumption takes place during the isovolumetric  
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Fig. 3. Starling Law 
contraction phase when the LV is trying to overcome the resistance caused by the AEDP in 
order to open the Aortic valve. The aim of counterpulsation is to lower AEDP, thereby 




Fig. 4. Myocardial Oxygen Supply and Demand 
6. Contractility  
Contractility is defined as the change in the force of contraction, independent of myocardial 
fiber length. Contractility inotropic performance can be increased by endogenous 
production of catecholamines or exogenous administration of vasopressors like 
norepinephrine (NE), dopamine, calcium etc. Myocardial contractility decreases wuth 
hypoxemia and drugs like barbiturates, procainamide, lidocaine, propranolol etc. 
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7. Ventricular function 
In order for us to appreciate the need for the IAB, we need to understand ventricular function, 
end diastolic volume and the Fick equation. Ventricular function in critical care is assessed by 
the Ejection Fraction (EF). EF is defined as the volume of blood ejected per beat (stroke volume 
or SV) divided by the volume in the LV prior to ejection, end diastolic volume (EDV). Stroke 
vol equals EDV minus end systolic volume (ESV). The equation for EF would then be: 
EF = EDV-ESV/EDV= SV/EDV 
Ventricular function is graded into four groups by two dimensional echocardiography 
according to ejection fraction as shown in fig 5 (Conolly HM & Kohl J 2012). 
 
LV Grade Ejection Fraction 
Grade 1 LV ≥ 55% 
Grade 2 LV 45 to 54% 
Grade 3 LV 30 to 44% 
Grade 4 LV ≤ 30% 
Fig. 5. LV Grade and Corresponding Ejection Fraction 
Diastolic volume index: EDV indexed to the patients body surface area (BSA) is another 
measure of ventricular performance. A normal index is considered less than 100ml/m². In 
patients with regurgitant valves and volume overload, the end diastolic volume index 
(EDVI) may be high despite preserved LV function. 
The Fick Equation: Defines the relationship between C.O and oxygen extraction. 
O2 consumption= C.O X O2 content difference (sao2-svo2) 
C.O = O2 consumption/O2 content difference (sao2-svo2) 
Therefore CO is inversely proportional to O2 content difference, assuming that O2 
consumption remains constant. A normal value for arterio-venous oxygen difference would 
be less than 5 ml/dl or 50ml/L. A low cardiac output state would encourage increased 
oxygen extraction, resulting in widening of arterio-venous o2 content of greater than 
5ml/dl. (Hensley et al.,1995 ) 
8. Heart rate 
Increase in the frequency of contraction increases C.O at a given filling pressure. This is 
called the staircase (Bowditch) effect. Reduction in diastolic time can result in reduction of 
ventricular filling, thus limiting C.O increase with tachycardia. An important corollary to 
remember is that the filling of coronary arteries takes place in diastole and tachycardia can 
compromise diastolic coronary filling. 
9. Coronary circulation and anatomy 
The myocardium is perfused during diastole through the coronary system (fig 6).  
The major vessels of the coronary circulation are the left main coronary that divides into left 
anterior descending and circumflex branches, and the right main coronary artery. The left 
and right coronary arteries originate at the base of the aorta from openings called the 
coronary ostia located just distal to the aortic valve leaflets.  
www.intechopen.com




Fig. 6. The Coronary System 
The left and right coronary arteries and their branches lie on the surface of the heart, and 
therefore are sometimes referred to as the epicardial coronary vessels. These vessels distribute 
blood flow to different regions of the heart muscle. When the vessels are not diseased, they 
have a low vascular resistance relative to their more distal and smaller branches that comprise 
the microvascular network. As in all vascular beds, it is the small arteries and arterioles in the 
microcirculation that are the primary sites of vascular resistance, and therefore the primary site 
for regulation of blood flow. The arterioles branch into numerous capillaries that lie adjacent to 
the cardiac myocytes. A high capillary-to-cardiomyocyte ratio and short diffusion distances 
ensure adequate oxygen delivery to the myocytes and removal of metabolic waste products 
from the cells (e.g., CO2 and H+). Capillary blood flow enters venules that join together to form 
cardiac veins that drain into the coronary sinus located on the posterior side of the heart, 
which in turn drain into the right atrium. There are also anterior cardiac veins and thebesian 
veins that drain directly into the cardiac chambers. The LAD supplies blood to the front 
(anterior-septal) portion of the heart and the LCX supplies the side (anterio-lateral) and back 
(posterior) of the left ventricle. The right coronary artery supplies blood to the ventricles, the 
right atrium (RA), the inferior portion of the myocardium and the sino-atrial node. The LAD 
give rise to various branches called the diagonals and marginal’s while the RCA bifurcates 
into the posterior descending artery (PDA) and the acute marginal artery. The RCA supplies 
blood to the inferior portion of the myocardium. 
10. Heart failure 
Forward heart failure or congestive heart failure is defined as the inability of the heart to keep 
up with its demand. Forward heart failure can lead to backward heart failure. Heart failure 
can be caused by structural heart disease, coronary artery disease, Cardiomyopathy or 
conduction disorders, more often than not requiring surgical correction. Conduction disorder 
can impair C.O by causing a too slow/fast heart rate, loss of atrial kick or loss of conduction. 
Left ventricular failure is directly related to the need for an IAB. Heart failure can be 
manifested as angina, crescendo or unstable angina or exercise induced angina. Heart failure 
causes ischemia and myocardial ischemia can be silent. Ninety seven percent of peri-operative 
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ischemia has been found to be silent (Hensley 1995). Silent ischemia can translate into peri-
operative infarct or ischemia both of which could cause heart failure. Left Ventricular failure 
can be divided into three stages. Stage 1 (fig 7) is manifested as vasoconstriction leading to 
decreased pumping efficiency, increased LV volume and pressure. These physiological events 
activate baroreceptors leading to increased heart rate, increased afterload (SVR), increased 
myocardial oxygen demand and ultimately an increase in preload (LVEDP). 
 
 
Fig. 7. Stage 1 Vasoconstriction 
Stage two (Fig 8) leads to hypervolemia as the heart tries to compensate with the additional 
afterload. There is a decrease in cardiac output and glomerular filtration pressure, further 
activating the Renin-Angiotensisn system. There is an increase in sodium and water 
reabsorption leading to an increase in preload and afterload. There is a decrease in cardiac  
 
 
Fig. 8. Stage 2 - Hypervolemia 
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output, decrease in oxygen supply, increase in heart rate and increase in oxygen demand. 
There is an increase in pulmonary artery wedge pressures. 
The final stage of LV failure (Fig 9) is the manifestation of tissue hypoxia. Decreased cardiac 
output, decreased MAP, decreased oxygenation coupled with pulmonary edema causes 
acceleration of anaerobic metabolism, lactic acid production, Tissue anoxia and finally tissue 
death. Its ideal to insert the IAB in stage one or  by stage two, so that we prevent the final 
stage of heart failure. 
 
 
Fig. 9. Stage 3 - Tissue Hypoxia and Apoptosis 
11. Indications for mechanical circulatory support 
Before we cite specific indications for IAB insertion, we should discuss indications for 
mechanical circulatory support. In other words, we should be able to delineate or define 
ventricular failure. LV failure would be defined as cardiac index (CI) of less than 1.8 
L/min/m² with a systolic blood pressure of less than 90 mmhg (ref: Hensley Martin) despite 
maximized preload (mean atrial pressure > 20 mmhg), optimized heart rate (> 80) and 
normalized ionized calcium. This could be extrapolated to RV failure except for the systolic 
blood pressure. RV work is the function of the difference between the RA and PA mean 
pressure. As the difference between the two approaches zero, pulmonary blood flow is passive 
and RV failure is present. RV failure can occur with or without pulmonary hypertension. 
Mechanical support is suggested when the above criteria are present despite maximum 
inotropic support. Maximum inotropic support can be defined as any two or more (High et 
al., 1995) of the following combinations: 
1. > 10 µg/kg/min of Dopamine 
2. > 10 µg/kg/min of Dobutamine 
3. > 0.2 µg/kg/min of Epinephrine 
4. > 0.75 µg/kg/min of Milrinone after loading dose 
5. > 10 µg/kg/min of Nor–epinephrine 
For patients with severe forms of LV failure, ventricular assist devices (VAD) are indicated. 
The initial indicated mechanical support in these scenarios is the IABP. Large and prolonged 
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inotrope infusion will only tend to increase the workload of the ventricle. The IABP does the 
exact opposite, decreases the workload of the heart. 
12. Indications for IAB insertion 
In cardiac surgery the IAB is indicated for the following situations: 
A. Pre-op predictors: 
1. Grade 3 to 4 LV dysfunction or ejection fraction (EF) of less than 0.30 (Dietl CA et 
al.,1996) 
2. Severe and/or multiple valvular disease with end stage myocardial impairment 
not including aortic regurgitation 
3. Anticipated prolonged CPB time 
4. Coronary artery disease (CAD) only partially correctible by grafting with 
concomitant LV dysfunction 
5. Persistent ST Changes before, during or after induction of general anesthesia 
6. Coronary obstruction via clot or otherwise 
B. Intra/post-op predictors: 
1. Pre/post CPB ischemia 
2. Incomplete repair or bypass 
3. Prolonged CPB time 
4. Large ventriculotomy or LV resection for LV aneurysm repair. 
5. Particulate or air embolus in coronary arteries. 
6. Persistent ST changes post CPB. 
Clinical indications for the IAB are listed below (fig 10 showcases benchmarks in 2005 for 
IAB use) 
1. Ventricular failure after myocardial infarction (MI) – (Barron et al., 2001) or acute 
myocardial infarction (AMI). As in all other cases the IAB will would decrease afterload 
and increase coronary perfusion. Early insertion is recommended to ameliorate the 
threatening extension of MI. 
2. Angina- chest pain is usually the initial stages of an MI and here again early insertion is 
recommended 
3. Unstable angina with or without ST segment elevation 
4. Cardiomyopathy- In the majority of cases when cardiomyopathy occurs the patient 
suffers from dilated cardiomyopathy and the IAB assist in raising mean blood pressure 
and reducing afterload. In a very few cases of initial stages of hypertrophic 
cardiomyopathy, where the ventricle tends to be a small volume ventricle (extremely 
thick myocardial wall), a sudden decrease in AEDP would result in insufficient volume 
left to fill the increased capacitance . This would actually result in a drop in MAP and 
systolic blood pressure, especially at an augmentation of 1:1 
5. Acute mitral valve regurgitation (Abid et al.,2002) and/or stenosis with LV rupture 
6. Aortic stenosis without aortic insufficiency (AI) or accompanied by mild AI 
7. Congestive heart failure 
8. Intractable ventricular arrhythmias secondary to ischemia or otherwise. In these cases 
IAB’s with fibre optic technology can be used to track rapid or irregular heart rhythms 
9. Ventricular irritability 
10. Bridge to transplant or destination therapy 
11. Support in the catheterization laboratory (Stone GW et al.,1997) for stenting or PTCA 
(Percutaneous Transluminal Coronary Angioplasty) 
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Fig. 10. BENCHMARK for IAB use (2005) 
12. Myocardial ischemia or stunning of the heart- In this scenario much of the myocardium 
has suffered reversible damage and scarring has occurred only in a portion of the heart. 
13. VSD (ventricular septal defect) - particularly post MI. This may be accompanied by 
papillary muscle rupture and acute mitral regurgitation 
14. Support in the General OR for patients with ongoing heart disease or a history of heart 
disease 
15. Transport (Sinclair TD & Verman HA,2009)for unstable patients 
16. Left main disease 
17. Cardiac contusion and/or trauma 
18. Septic shock or pre-shock syndrome 
19. Pulsatile flow (Onorati F et al.,2009)during CPB 
Freedman coined the term “Myoconservation” (Quaal 1993). It is defined as the 
hemodynamic support provided within the crucial window of opportunity, ensuring that 
enough myocardium remains viable to permit normal function of the heart following 
definitive coronary therapy-whether it be CABG or coronary stenting/PTCA. The IAB is one 
of the very important modalities available to the cardiac surgeon/cardiologist which 
supports myoconservation by supporting the coronary circulation, supporting the systemic 
circulation, reduction in LV stress and reduction in LV workload.  
Miller et al in 1986 summarize “The result of our clinical experience suggest that more 
aggressive use of IAB is likely to save lives of coronary disease patients who develop severe 
complications of their disease. There have been no deaths reported among our patients with 
refractory unstable angina who had an IAB inserted and all evidence suggests that short of 
actually opening the vessel to obtain relief from angina, IAB insertion is the most effective 
method to treat these patients”  
More recent studies (Christenson JT 1999) have confirmed the efficacy of pre-operative IAB 
use in high-risk coronary patients. 
13. Absolute contraindications for IAB insertion 
1. Aortic regurgitation or insufficiency. In this physiology, raising AEDP would result in 
increase of regurgitant factor thereby increasing workload of the heart. In instances of 
mild AI a decision can be made if the benefits outweigh the risks. 
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2. Aortic dissection. Precludes IAB insertion. Attempting to Place an IAB in this situation 
may lead to placement in the false lumen or at the very least increase circulation into 
the false lumen. 
14. Relative contraindications for IAB insertion 
1. Severe peripheral vascular disease (PVD). Although this sometimes precludes insertion, 
we have had some experience with this. A discussion on PVD patients will be 
conducted a little later. 
2. Unresected thoracic, abdominal or thoraco-abdominal aneurysm. An insertion of a 
mechanical device like the IAB and the counterpulsation of such a device against a 
diseased aortic wall may result in aortic dissection 
3. Sepsis or infection 
4. Severe thrombocytopenia 
5. Coagulopathy or coagulopathic disorder 
6. End stage terminal disease 
7. End stage cardiomyopathy unless bridge to transplant/destination therapy 
8. Severe atherosclerosis 
15. Pre-insertion predictors of risks associated with IAB insertion 
1. Age- Increased age appears to be an increased risk. It is probably because of increased 
atherosclerosis associated with increased age (Goldberger 1986). There are other studies 
reporting inconsistent results. 
2. Gender- women tend to have a greater risk of complication due to their smaller stature. 
This is probably due to the smaller lumen size of the femoral artery in women. The IAB 
catheter was expected to occupy greater lumen space in women thereby increasing the 
likelihood of ischemia and/or thrombus formation. Women are 1.6 to 1.8 more likely to 
experience limb ischemia/vascular complications than men (Skillman JJ et al, 1988). 
3. Peripheral vascular disease (PVD) - These patients have higher likelihood for IAB 
complications due to insertion difficulties. Gottlieb suggested a three times likelihood 
for complications (Gottlieb SO et al.,1984), others  have suggested less (Skillman JJ et 
al,.1988). 
4. Type-II diabetes- Due to severe and diffuse atherosclerotic disease, higher incidence of 
hypertension and dampened resistance to bacterial contamination, diabetics tend to 
have a higher risk of complication post IAB. Some investigators found that diabetics 
(Wasfie T et al.,1988) had a 22% incidence of complications post IAB insertion as 
compared to 14% for non-diabetics. For insulin dependent diabetes a higher 
complication rate of 34% (Alderman JD et al., 1987) was suggested. 
5. Duration of IAB therapy- Findings for the duration of safe use of IAB therapy remain 
inconclusive (Quaal 1993) 
16. Complications of IAB insertion 
1. Loss of pedal pulses- Occurs in 15 – 25% of patients (funk M et al.,1989). Asymptomatic 
loss occurs transiently without resulting in limb ischemia and usually returns 
spontaneously or after IAB removal. 
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2. Limb ischemia- Occurs in 12 – 47% patients and is the most frequently reported 
complication (Curtis JJ et al., 1988). This may result from decreased cardiac output 
subsequent to heart failure, elevated SVR, low output syndrome, intimal injury or 
dissection, vessel catheter discrepancy, catheter occlusion or distal thrombo-embolism. 
Limb ischemia usually preceded by pain in the affected limb, change in pallor, cyanotic 
color changes, mottling, decreases in sensation, motor function loss, decrease in 
temperatures in extremity and loss of pedal pulses. Treatment is usually done by 
removal of IAB, thrombectomy, femoro-popiteal grafting and/or papaverine 
administration. 
3. Thromboembolism- Percutaneous insertion/removal of IAB may result in dislodging of 
plaques or clots into the renal, splanchnic, hepatic or peripheral arteries. Clots can be 
seen while removing IAB catheters. It is our institutional policy to have some sort of 
anti-coagulation during IAB therapy. Although Low molecular weight Dextran has 
been used, heparin is preferable as it can be reversed with protamine. Generally 
maintaining the aPTT 1.5 – 2 times normal is sufficient to prevent formation of 
thrombin, thereby protecting from subsequent embolism. It is also recommended to 
flush the IAB catheter with heparinized saline prior to insertion. The only incidence 
where this may not be necessary is when the patient is fully heparinized and on CPB. It 
is always a good practice even in this situation to flush with heparinized saline. At 
Southlake we use pre-mixed heparinized saline bags with 5000 units of heparin in 
500ml of saline. 
4. Compartment syndrome- The legs and thighs of humans are made up of compartments 
containing bone, muscle, nerve tissue and blood vessels, surrounded by a fibrous 
membrane or fascia. Compartment syndrome is caused by an increased pressure within 
the non-distensible fascial space reducing capillary blood flow which in turn 
compromises enclosed fascial tissue. A fasciotomy can be performed to relieve the 
pressure. 
5. Aortic Dissection- Is the most serious of complications from IAB insertion. Often 
unrecognized until removal or until IAB therapy is discontinued resulting in 
hemodynamic instability and death. Diagnosis is confirmed upon autopsy. Isner in 1980 
found an incidence of aortic dissection in 36% of IAB patients (Isner JM et al,. 1980).With 
the advent of smaller French sizes in IAB catheters and better techniques and training, 
incidence of aortic dissection as a direct consequence of IAB insertion has drastically 
reduced .Symptoms of aortic dissection include severe back and/or abdominal pain, 
falling hematocrit and mediastinal enlargement. Aortic Dissection has to be treated 
aggressively and immediately by attempting to repair the dissection in the operating 
room. 
6. Local injury- False aneurysm formation, hematoma, lymphedema, lymph fistula, 
wound hemorrhage, laceration of the femoral/iliac artery or the aorta are common 
complications and can be treated by evacuation and/or arterial repair. 
7. Infective complication- Local wound infection is possible necessitating debridement, 
drainage, systemic antibiotics and rare cases removal. Sterility is very important while 
inserting the IAB whether in the peri-operative setting or otherwise. Generally the thigh 
is prepared by applying betadine prior to insertion and is covered by sterile dressing 
after insertion and anchorage of the catheter by two sutures. 
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8. IAB rupture/entrapment- IAB rupture is rare but immediate removal/replacement is 
required. Rupture is more likely in women and patients with smaller size and usually 
occurs because of the constant contact between IAB membrane and atherosclerotic 
plaque on the femoral arterial/Aorta walls. The most common sign of IAB leak is blood 
in the drive line (fig 11). IAB leak can cause either a helium embolus (in instants of 
patient hypotension where helium pressure within the IAB exceeds blood pressure in 
the aorta) or entrapment of the catheter. The leak can cause a clot to form within the 
catheter resulting in prevention of removal of the catheter at the time of IAB removal. 
This may necessitate a cut down removal of the IAB catheter. 
 
 
Fig. 11. IAB Catheter with Blood in Drive Line and Balloon 
9. Hematologic effects- Long term use of IAB has been associated with increased 
destruction of red cells and thrombocytopenia. The degree of decrease appears to be 
related to the duration of therapy (McCabe 1978) 
10. Malposition of the IAB catheter- If positioned too high, the IAB may occlude blood 
flowing to the head vessels causing cerebral ischemia and or embolism. If positioned 
too low it may occlude the renal arteries thereby causing renal ischemia/perfusion and 
non-optimal coronary perfusion/afterload reduction. 
17. Insertion techniques 
1. Cut down technique- By 1978 the IAB was a 12fr catheter and prior to that year, cut 
down insertion was common. Initially, the common femoral artery is dissected and the 
vascular fascia is opened. With a retractor the femoral artery can be dissected up to a 
length of 5 cms and umbilical tapes are placed around and behind the femoral artery. 
Heparin 5000u is administered and the IAB catheter is introduced at an angle to the 
femoral artery. Placement is confirmed and augmentation initiated. This technique can 
also be used in patients where femoral pulse is not palpable or where difficulty of 
insertion is anticipated as in patients suffering from PVD. 
2. Percutaneous (Seldinger) technique: An 18 gauge cannula is introduced into the 
common femoral artery at a 45 degree angle or less. The guide wire is advanced 
through the needle and the needle removed. The tissue tract around the arterial 
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puncture is then dilated by the dilator provided in the IAB catheter set. The introducer-
dilator set is advanced over the guidewire. Finally the dilator is removed and the IAB 
catheter advanced over the guidewire. The IAB is introduced over the guide wire and 
placed in the second or third intercostal space. It is recommended to maintain a 
continuous flush of the IAB catheter with heparinized saline (1000u in 500ml) after 
placement. It is also recommended to periodically flush the arterial line from the IAB in 
order to prevent clotting of the arterial line coming from the IAB catheter. The 
manufacturer recommends the IAB catheter to be anchored with two sutures to the 
subcutaneous tissue of the thigh (Fig 12) at the anchors provided on the side of the base 
of the catheter or by the sutureless securement device provided. 
 
 
Fig. 12. Proper Anchoring of the IAB Catheter 
3. Sheathless insertion- Initially IAB catheters were enveloped by sheaths with bigger 
French sizes. E.g. The 8Fr IAB catheter has a sheath whose outer diameter is 10Fr. By 
not using the sheath, the practitioner is reducing trauma to the groin and femoral 
artery. Current IAB catheters of 7 and 7.5Fr are inserted in our institution without the 
sheath. Sheathless insertion also reduces the length of catheter indwelling in the tissue, 
thereby reducing limb ischemia. 
4. Subclavian insertion- Currently the manufacturer and FDA (Food and Drug 
Administration) recommends (in their IFU-instruction for use manual) femoral 
insertion of all IAB catheters. IAB catheters have regulatory clearance for femoral 
insertion and are labeled as such. There are situations where the subclavian artery has 
been used in order to avoid an aorto-iliac stenosis. A subclavicular incision is done and 
the subclavian artery isolated via cut down. An IAB catheter is placed antegrade down 
the descending thoracic aorta. 
5. Brachial insertion- The brachial artery can be used as a point of insertion where the 
patients have bilateral obstructive femoral and iliac disease and/or the patient has 
bilateral femoro-popliteal graft. Due to discomfort associated with positioning, the 
authors would recommend only in patients who are intubated and on a ventilator. Care 
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should be taken to insert the IAB on the left rather than the right side. As right sided 
insertion would not give the IAB enough length to cross the aortic arch and lie in the 
descending Aorta. We came across a 74 years female diagnosed with coronary artery 
disease (CAD) and triple vessel disease (TVD) who had aorto-bifemoral grafts inserted 
in 2004. Her risk factors included hypertension, active smoking history, type 2 Diabetes 
and previous MI. Her EF was only 28%, she had moderate MR, moderate PAH and left 
carotid bruit. She was turned down for surgery. She presented in emergency with 
angina. Had a syncopal episode with rapid atrial fibrillation. She was cardioverted 
twice and transported to the cath lab for IAB insertion. An IAB (Fig 13) was initially 
inserted through the right brachial artery and was observed via fluoroscopy to lie in the 
aortic arch. The IAB was then removed and re-inserted via the left brachial artery and 
inserted antegrade down the thoracic aorta. Augmentation was initiated, the patient 




Fig. 13. Transbrachial Insertion 
6. Transthoracic Insertion- In instances where the IAB insertion is precluded due to severe 
PVD or has been tried and failed, The IAB catheter can be introduced down the aorta in 
operative room situations. We had one such patient- a 65 year old male with active 
smoking history, no hypertension/daibetic history and a history of pericarditis in 2003. 
He had a history of severe PVD with bilateral femoral claudication and severe pain in 
his legs. Angiogram was facilitated through the right radial approach. He underwent 
CPB and uneventful CABG to his LAD and PIV (posterior interventricular artery). The 
patient had a hypotensive episode during sternal closure, CPB was re-initiated, 
mammary spasm suspected and a vein graft anastomosed distal to the previous 
mammary artery anastomosis. We were unable to separate from CPB, at this time a 
decision was made to insert an IAB transfemorally. Transfemoral insertion failed and an 
IAB catheter (Fig 14) was placed antegrade down the thoracic aorta. At this point the 
patient was able to separate from CPB. Due to suspicion of myocardial edema, late 
sternal closure was decided upon, the skin closed, dressing placed and patient 
transported to the CVICU. The patient was taken back to the OR post-op day 3, the IAB 
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removed and the chest closed. The patient was extubated post-op day 9 and discharged 
after 25 days. No post-operative morbidity noted other than associate with his history 
of peripheral vascular disease (Datt B 2007) 
 
 
Fig. 14. Trans-thoracic Insertion of IAB Catheter 
18. Mechanics of IAB functioning  
IAB therapy is often referred to as counterpulsation therapy as the balloon inflates in 
diastole or counter to the hearts contraction (systole). The IAB is a polyethylene balloon 
catheter placed percutaneously in the thoracic aorta through the groin (Fig 15). 
 
 
Fig. 15. Femoral Insertion of IAB Catheter 
Balloon inflation actively pushes blood into the coronary arteries, increasing myocardial 
oxygen supply. Balloon deflation decrease AEDP thereby directly reducing myocardial 
work load and myocardial oxygen consumption by reducing the time period for 
isovolumetric contraction. This gives the heart time to rest and gives a chance for 
hibernating myocardium to recover. 
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The IAB is connected by a driveline to a helium chamber or pressurized gas reservoir which 
is connected to the IAB catheter via a solenoid valve. The inflation or helium supply is 
linked to a trigger for the balloon which is usually a synchronized ECG (Electrocardiogram) 
or the patient’s blood pressure. Earlier on in IAB development CO2 was used due to its high 
solubility and safety in case of balloon leak/rupture and gas embolization. Helium started 
being used due to its smaller Reynold’s number (lower density), thereby allowing a smaller 
drive line/catheter. Smaller balloon catheters improved gas shuttle speeds, reduced trauma 
to the groin and resulted in fewer complications post-insertion. 
The balloon is usually placed 2 cms below the subclavian artery in the second to third 
intercostals space. This optimizes coronary perfusion and decreases the chances for renal 




Fig. 16. Chest X-ray Confirmation of IAB Placement 
Synchronization of the IAB is achieved usually by using the R wave of the QRS complex to 
deflate the IAB catheter. In the operating room some practitioners tend to use pressure 
trigger to circumvent electrical interference from the cautery or other devices. If the patient 
is pacer dependent, the pacer spike can also be use to trigger IAB deflation. Correct timing is 
verified by observing the dicrotic notch on the arterial pressure waveform on the balloon 
console and making sure that balloon inflation takes place just after the dicrotic notch (aortic 
valve closure) and deflates prior to LV ejection (R wave on QRS complex-Fig 17 & Fig 18) 
While using the pressure trigger, it’s important to use the dicrotic notch as the marker for 
inflation. This will prevent the balloon from impinging on LV ejection and adding to the 
hearts afterload. 
At Southlake we use the Maquet IAB console (fig 19) CS 100 which has an auto feature for 
timing. Another IAB console which the reader may come across would be the ACAT II 
WAVE console (fig 20) marketed by Arrow international. 
The console uses a unique algorithm to establish the initial timing using the ECG or arterial 
pressure waveforms. It will also automatically readjust the inflation and deflation timing for 
changes in heart rate or rhythm. This allows for ease of nursing care post-operatively and 
decreases the necessity of the perfusionist except for troubleshooting. The IAB has three 
choices for augmentation. 1:1, 1:2 and 1:3. The IAB is generally initiated at 1:2 in order to be 
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able to check the timing of the IAB catheter. The timing can be verified by using the inflation 
interval option on the console. Generally at a higher heart rate (>100), a better augmentation 
pressure is achieved by lowering the ratio to 1:2 or 1:3. The (stroke) volume of the balloon 
used is dependent on the size of the balloon and is chosen based on the height of the target 
patient (fig 21). 
Recently, due to the reduction in french size of the IAB catheters to 7Fr, it is possible to 








Fig. 18. Proper IAB Timing 
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Fig. 20. ACAT II WAVE Arrow IABP 
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Fig. 21. Size Selection Criteria for IAB Catheter 
19. Timing errors 
There are four major timing errors with the IAB. The IAB is usually timed at a 1:2 ratio (one 
inflation every second heart beat) and the deflation is triggered off the R wave in the QRS 
complex. If the IAB is timed improperly, it can actually add to the afterload of the heart by 
inflating prior to the closure of the aortic valve. In this situation the cardio-vascular 
hemodynamics can deteriorate quickly and it is important for the practitioner to understand 
and avoid these errors. 
1. Early inflation: The waveform shows inflation of IAB prior to dicrotic notch, diastolic 
augmentation encroaches into systole (fig 22) and is not hard to miss. The physiological 
effects would be potential premature closure of aortic valve, increase in LVEDP, 
LVEDV (Left Ventricular End Diastolic Volume) and PCWP (Pulmonary Capillary 
Wedge Pressure). The net effect would increase afterload, myocardial oxygen 
consumption and possibility of adding to Aortic regurgitation. 
2. Late inflation: Inflation of IAB after the dicrotic notch, indicated by the lack of a sharp 
“V” on the waveform (fig 23). The physiological effects include sub-optimal coronary 
perfusion and decreased diastolic augmentation. 
3. Early deflation: Viewed as a sharp drop in the waveform after diastolic augmentation. 
Assisted AEDP can be equal to the unassisted AEDP (fig 24). There may be little or no 
decrease in assisted systolic pressure. There is an absence of a sharp”v” or pore-systolic 
dip. This error will also lead to sub-optimal coronary perfusion, mvo2 and afterload 
reduction. There is also a potential for causing retrograde coronary and carotid blood 
flow with the latter causing an increase in angina.  
4. Late deflation: Possibly the most dangerous of all timing errors. Rate of rise of assisted 
systolic pressure may be prolonged. Assisted AEDP may be equal to unassisted AEDP. 
Diastolic augmentation waveform may be dampened (fig 25), depending on how late 
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the deflation is. Physiologically, afterload reduction is absent. IAB is actually impeding 
LV ejection and increasing afterload. Isovolumetric contraction phase increases along 













Fig. 23. Late Inflation  
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Fig. 24. Early Deflation  
 
 
Fig. 25. Late Deflation  
20. IAB weaning 
IAB weaning is usually done when the following physiological parameters are observed in 
target patients. 
1. No afterload reduction as seen on balloon waveform 
2. Increased urine output 
3. Improved LV function and hemodynamics 
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4. Cessation and/or improvement of ventricular and/or atrial arrhythmias 
5. Cessation or reduction of angina 
6. When transportation or operative procedure (revascularization of left main or 
aortic/mitral valve repair/replacement) is completed and the patient hemodynamics 
appear to be stable 
7. When the shock phase has been successfully tided over 
The IAB is generally weaned by reducing the ratio from 1:1 to 1:3, after which the 
augmentation volume of the balloon catheter can be reduced. If the IAB volume is being 
decreased as a part of the weaning process, ensure adequate movement of the IAB catheter 
in order to minimize clotting or thrombus formation. The IAB is never turned off when the 
IAB catheter lies in the aorta due to the risk of thrombus formation. Afterload reduction by 
the IAB can be explained via numbers. The stroke volume of an average sized patients in 
normal health is usually 70 to 80 ml. In a patient in compromised cardio-vascular state, this 
stroke volume is reduced to 40 or 50ml. What a 40cc IAB catheter does is to complement the 
native stroke volume of 30-40ml until hibernating myocardium recovery and myocardial 
rest result in an increased stroke volume of that patient. 
21. Advancements in IAB catheter and IAB console technology 
Considerable improvements have been made in IAB catheter and console technology in the 
more than 40 years since counterpulsation was introduced to clinical practice. Early IABP 
consoles required intensive user intervention, as all aspects of console operation were 
manually controlled. Early IAB catheters were 12 Fr. and required surgical insertion via a 
cutdown to the femoral artery. Surgical insertion could take 1-2 hours and complication 
rates were high. In 1979, IAB catheter insertion improved significantly with the 
development of percutaneous IAB insertion. Insertion time was reduced, typically to 15 
minutes. 
Additional improvements to the catheter in the early years included the addition of an inner 
lumen to facilitate wire-guided insertion and the lumen could then be used to monitor the 
arterial blood pressure. Prefolding of the membrane during manufacturing eliminated the 
need for the clinician to wrap the membrane prior to insertion through the introducer 
sheath. Catheters were also made smaller, from 12 Fr. to 10.5 Fr. and then to 9.5 Fr. Catheters 
are now 7 and 7.5 Fr. and this has helped reduce the incidence of limb ischemia to less than 
3%. Reducing the catheter shaft diameter required a significant change to the way catheters 
were designed. With early dual lumen catheters, the inner lumen used for wire guiding the 
insertion and monitoring the arterial pressure was a separate catheter within the balloon 
catheter gas lumen. With the development of a co-lumen design where the two lumens of 
the catheter were extruded together with the inner and outer lumens sharing a common 
wall, the catheter diameter was reduced while maintaining the gas shuttle lumen and 
maximizing the inner lumen to accommodate the largest guide wire possible. The range of 
balloon membrane sizes was also expanded over the years from 40 cc in the early days of 
counterpulsation to 25 cc, 34 cc, 40 cc, and 50 cc IAB membranes. The size of balloon used is 
determined by patient height. The most recent improvement in IAB catheter technology has 
been the addition of a fiber optic pressure sensor to acquire the arterial pressure signal. This 
technology is immune to artifact, resulting in a high fidelity arterial pressure waveform for 
accurate IAB timing. 
While innovations in IAB catheter technology were being developed, improvements in IAB 
console technology were also occurring. Major improvements to the console over the years 
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have been aimed at making the algorithms smarter, the pneumatics faster, and the consoles 
smaller and lighter. Early consoles required constant operator intervention to maintain 
optimal triggering and timing. Improvements to the algorithms in the console resulted in 
the automation of timing so that once the operator established the initial timing, the console 
could adjust the timing for changes in patient heart rate and rhythm. Console pneumatic 
improvements reduced IAB inflation and deflation time, which was important for tracking 
tachycardic rhythms. Consoles were made smaller and lighter to facilitate transport by 
aircraft or ambulance. 
The most significant improvement to console design occurred with the development of fully 
automated operation. With this capability, the console can automatically select the most 
reliable trigger and establish initial timing. It will then automatically readjust timing for 
changes in heart rate and rhythm, using advanced algorithms to track predictable (regular) 
as well as unpredictable (irregular) rhythms. The algorithms will also select an alternate 
trigger if the current trigger is lost. This automation, along with smaller fiber optic catheters 
offers the clinician the most advanced IAB counterpulsation system for optimal patient 
benefit. 
22. Intra-aortic balloon pump use during percutaneous coronary angioplasty 
The Intra-aortic balloon pump (IABP) can also provide important hemodynamic support 
during complex percutaneous coronary intervention (PCI), both in the elective setting, and 
for acute coronary syndromes, including ST segment elevation myocardial infarction. 
Modern coronary interventions can generally be performed to a wide array of patient 
subsets with low risk of procedural complications. However, optimal patient outcomes in 
PCI require identification of higher risk patients, and attempts to modify those risks. One of 
the main predictors of outcomes in PCI is Left Ventricular dysfunction, i.e. Ejection fraction 
<30%. The availability of mechanical support helps provide "backup" or reserve during the 
procedure and decreases the risk of hemodynamic compromise. Typically, mechanical 
support is initiated prior to commencing PCI, and removed shortly after successful PCI. 
Intra-aortic balloon pump use results in the dual benefits of increased peak diastolic 
pressure, while lowering the end-systolic pressure. There is a resultant reduction in after-
load (Perera D et al,2010) and improved coronary perfusion, which leads to improved 
myocardial oxygen supply, with decreased myocardial energy demands.  
The common scenarios for IABP use in PCI include: 
1. Acute Coronary Syndromes (ACS) / ST elevation Myocardial Infarction (STEMI), 
complicated by cardiogenic Shock, due to LV systolic dysfunction or a mechanical 
complications such as acute mitral regurgitation or ventricular septal defect. 
2. PCI in a coronary artery supplying a large territory of myocardium, typically with 
underlying Left ventricular dysfunction (practically speaking, Grade 3 or worse - EF < 
30%). Specific scenarios include i) coronary intervention on a diseased vessel that also 
supplies flow to another occluded vessel (via channels, called collateral arteries, that fill 
that territory in retrograde fashion), ii) unprotected left main stenting, iii) PCI to the 
only patent artery iv) PCI with concomitant valvular disease, if anticipated 
deterioration in the valvular disease (ex. patients with at least moderate ischemic mitral 
regurgitation, and planned PCI that could worsen degree of regurgitation). 
3. If patients have clinical signs of abnormal resting hemodynamics, prior to PCI: low 
systolic blood pressure (SBP) <100, with objective or clinical suspicion of elevated left 
heart filling pressures - pulmonary capillary wedge pressure >20mmHg. 
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4. Survival Dependent vessel: Any one artery supplying a sufficient amount of 
myocardium such that (in the opinion of the cardiologist) closure of the vessel would be 
fatal. 
It should be noted that there is considerable practice variation with Intra-aortic balloon 
support during high risk coronary intervention. Recognizing the higher risk of access 
related and other vascular complications with its insertion, some clinicians prefer to have 
the IABP readily available and use it only if hemodynamic compromise develops. . One trial 
conducted in centers in the United Kingdom, The Balloon Pump-Assisted Coronary 
Intervention Study, assessed whether routine intra-aortic balloon pump insertion, prior to 
PCI, reduced the risk of major adverse cardiac and cardiovascular events in patients with 
severe left ventricular dysfunction and advanced coronary disease. The results of this trial 
involving just over 300 randomized patients did not support routine use, given no 
difference between the groups. Clinical judgment is certainly exercised in situations (such as 
those described above) where the IABP is inserted "pre-emptively", with anticipated 
hemodynamic stress during PCI. 
23. Counterpulsation – An anesthesiologists perspective 
As an anaesthetist, working in the perioperative care of cardiac surgery patients for the last 
20 years, I have observed a significant change in the attitudes and uses of the intra aortic 
balloon pump. I have watched the use of the IABP change from a last resort salvage 
technique for the patient on maximal inotropes with low output syndrome and a dismal 
prognosis, to a first line tool aiming for preservation of myocardial tissue in unstable cardiac 
surgery patients. The presumed IABP’s favorable myocardial oxygen supply/demand 
profile and the ease of percutaneous insertion have been instrumental in this change (Trost 
JC 2006).  
In our institution IABPs are often inserted in preoperative cardiac surgery patients: who are 
experiencing unstable angina, especially post myocardial infarction, not responsive to 
standard non-invasive therapies; that have low output syndrome or congestive heart failure 
secondary to severe left ventricular dysfunction or mechanical complications such as a 
ventricular septal defect or mitral regurgitation induced by a myocardial infarction ; and 
rarely who have acute myocardial ischemia causing intractable arrhythmias. It appears that 
the earlier the balloon is placed in a hemodynamically struggling patient, the more stable 
the patient is in the post-operative period. This practice is consistent with the Task Force on 
Practice Guidelines of the American Heart Association and American College of Cardiology 
(Ryan TJ 1999). Frequently, IABPs are inserted for preoperative cardiac surgery patients with 
symptomatic left main disease. The intention of the IABP is the preservation of viable 
ïschemic myocardial tissue. The mechanism of the preservation may relate more to 
decreased myocardial demand and collateral flow as Kimura showed that in the presence of 
a coronary artery stenosis of greater than 90% the IABP diastolic augmentation did not 
result in an increased post-stenotic pressure (Kimura A 1996). The insertion of the IABP into 
the aforementioned patients facilitates the anaesthetist’s ability to maintain cardiovascular 
stability and a favourable myocardial oxygen supply/delivery ratio at induction, 
maintenance and release from bypass. Replace with" The importance and validity of the 
IABP in maintaining a favorable myocardial oxygen supply/demand ratio is realized in the 
post-operative period (Christenson 1997).  
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Intraoperatively, IABPs are inserted into our patients when difficulty to wean from the 
bypass machine is anticipated due to instability in the pre-bypass or bypass period or for 
failure to wean from the bypass machine, once reversible causes for the failure are ruled out. 
There may be a survival advantage to placing the IABP prior to coming off bypass based on 
one review. Delaying insertion of the IABP in the unstable perioperative patient who is 
unresponsive to reasonable doses of inotropes or who has rapidly accelerating inotropic 
requirements may have deleterious effects. Theoretically this is supported by the following 
facts. High inotropic doses increase myocardial inotropy and tension resulting in increased 
myocardial oxygen demands. Impaired diastolic relaxation and increased ectopy and 
afterload, as seen with certain inotropes, may further tip the myocardial supply/demand 
balance in favour of demand (Katz AM 1990). Myocardial injury may be further exacerbated 
by the inotropes increased delivery of calcium to the cell, overcoming the ischemic 
myocardium’s presumed protective attempt at limiting available calcium. Early insertion of 
the IABP in the unstable post-bypass patient appears to theoretically and anecdotally 
improve outcome (Poole Wilson PA 1990).  
Postoperative insertion of the IABP in the majority of our cases is for myocardial failure or 
signs of ischemia. Many times there is a dramatic improvement post balloon insertion. The 
mechanism producing this improvement is often not clear .Possibilities include a heightened 
diastolic pressure overcoming decreased coronary flow secondary to low mean arterial 
pressure, left internal mammary spasm or air within a coronary artery, improved collateral 
flow (Kern MJ 1991), or decreased demands secondary to decreased afterload and preload 
resulting in decreased myocardial wall tension. The IABP often assists in stabilization of the 
patient, although more definitive therapy may be required. The location of the ischemia, as 
visualized by the electrocardiogram and often echocardiogram, the magnitude of the failure, 
the surgical knowledge of the coronary disease and surgery and the response to the IABP 
determine the need for further management.  
We have come to use IABP’s earlier, and the indications have broadened to include all 
stages of the perioperative care. The theoretical protective effect of the IABP with respect to 
the myocardial supply/demand ratio, the ease of insertion of the IABP by the percutaneous 
route clinical observations and limited studies support this practice. 
24. Conclusion 
The IABP since its advent in 1960 has progressively become an indispensable technology 
available to the healthcare team in cardiology and cardiac surgery. Improvements in 
membrane technology have reduced the french sizes required to be used for femoral 
percutaneous insertion. This has minimized trauma caused by femoral insertion of the IAB 
catheter. 
Earlier on in my training as a perfusionist, old school cardiac surgeons always inserted 
IAB’s later rather than sooner. Counterpulsation technology was always thought to be a last 
ditch effort and mortality was thought to be higher once the IAB was inserted. This 
perception has changed radically over the last twenty years. 
The ease of insertion (compared to VAD’s and artificial lungs), ease of removal, low risk of 
complications and availability in the peri/post and pre-operative environment in a hospital 
setting has made counterpulsation an ideal choice to treat acute or chronic heart failure. 
There is no doubt at this point of the positive effects of counterpulsation on early mortality 
and post-operative morbidity in cardiac surgery. In instances where IAB insertion is 
www.intechopen.com
Intra-Aortic Balloon Counterpulsation Therapy 
and Its Role in Optimizing Outcomes in Cardiac Surgery 
 
69 
precluded or insertion has failed, transthoracic (in a peri-operative setting), transbrachial or 
subclavian insertion can also be performed with a positive impact on survival. Morbidity 
and mortality however are higher in these kinds of cases and may have to do with the pre-
operative risk factors these patients come into surgery for. The cardiac surgeon has to tread 
the fine line between deciding the optimal timing for IAB insertion by weighing the benefits 
of counterpulsation vs the low risk of complications. It is increasingly being understood that 
for a poor LV and /or a patient with a risk of peri-operative infarct, it is optimal to insert an 
IAB sooner rather than later. The catheter can easily be removed first or second post-
operative day after the surgery has performed and the risk for infarct been mitigated. 
At Southlake, a 380 bed community hospital, we perform approximately 1000 heart surgeries 
and 3000 PTCA’s annually. In support we insert 250 IAB catheters annually and are the largest 
IAB user in Ontario-Canada. We are a comparatively new heart centre, having started our 
cardiac surgery program in 2004. Aggressive use of counterpulsation reflects the new belief in 
early IAB insertion in cardiac patients at risk of pre, peri or post-operative infarct. Transfusion 
rates at SRHC for CABG in the first half of 2009 approximate 26% (Fig 26). 
 


























Fig. 26. Red Blood Cell Transfusion Rate for 2009 at SRHC. 
Mortality at SRHC for late 2009 (July to Dec 2009) was based on Toronto Risk Score (TRS). 
The observed mortality ranged from 0.5% (TRS 2-4) to 8.5% (TRS >8) as shown in fig 27. 
 
 
Fig. 27. Observed and Expected Mortality at SRHC by Toronto Risk Score 
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It is the opinion of the authors that the above average results in morbidity and mortality for 
our cardiac patients may partly be due to the aggressive use of IAB in cardiac procedures. 
Aggressive use of counterpulsation therapy preempts infarction for the cardiac patient and 
in turn improves outcomes in cardiac surgery. 
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